Trial Profile
Qualitative Interviews and Survey: Understanding how the attributes of Relvar/Breo convey patient benefits – Asthma and COPD
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 13 Jul 2023
Price :
$35
*
At a glance
- Drugs Vilanterol/fluticasone furoate (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 21 Aug 2018 New trial record
- 13 Aug 2018 Results published in the Advances in Therapy